



Late-Breaking Clinical Trials Submission Guidelines

The Heart Rhythm Society recognizes that exciting and rapidly evolving research was not concluded in time for the February 15, 2021 abstract submission deadline. To highlight timely and novel work at #HRS2021, the Heart Rhythm 2021 Program Committee will develop peer-reviewed sessions of late-breaking science and late-breaking clinical trials that allows for later submission.

Important Information

The Late Breaking Clinical Trials submission site will open **Thursday, April 15, 2021**. *Each abstract submission will require a fee of \$175 for HRS members and \$250 for non-members. The submission fee will directly fund additional travel grants to assist fellows-in-training and support enhancements to the presentation of abstracts. The Submitting Author will be charged a non-refundable submission fee for each abstract. Payments must be made by credit card during the submission process. Visa, MasterCard, and American Express are accepted.*

All submissions must be received no later than **Thursday, May 13, 2021, 11:59 p.m. ET**. Abstracts submitted after this deadline will not be considered. **Authors will be notified about the acceptance/rejection of their abstract on June 7, 2021 via email.**

Abstract Author Designation

The Submitting Author is the Presenting Author. All correspondence for the abstract will be directed to the Submitting Author, their information should be reviewed to ensure that current and correct email address information is listed. This designation should be carefully considered before initiating the abstract submission process. Once the abstract has been submitted, the Submitting Presenting Author cannot be changed.

Criteria

Evaluation will be based on the following criteria:

1. Impact of the research
2. Novelty and rigor of the study design
3. Clinical endpoints
4. Quality of the statistical plan

Rules for Submission Eligibility

- If an abstract submission has already been accepted for the #HRS2021 meeting, it will not be eligible for the Late Breaking Clinical Trials session.”
- Submissions are not eligible for consideration if the manuscript of the submission will be published prior to #HRS2021.
- Submissions are not eligible for consideration if the trial results have been presented at a major international meeting held prior to #HRS2021.
- Submissions that appear to be redundant versions of a single study and/or selling a product versus discussing the science will be rejected.

Investigator/Presenting Author Requirements

- The first investigator listed in the abstract shall be considered the presenter. Only one investigator per trial may be considered the presenter.
- The submitting investigator must guarantee that all co-authors are familiar with the data, agree with the stated results, and have agreed to be included as authors.
- If an investigator belongs to multiple submissions, the investigator's name must be identical in each submission. This will ensure consistency and assist in the indexing process for all #HRS2021 publications.
- A completed submission constitutes a commitment by an investigator to present if accepted.

Late Breaking Clinical Trials Categories:

1. **Late-Breaking Randomized Clinical Trials:** First-time presentation of primary or major secondary results from a prospective, randomized clinical trial.

2. **Late-Breaking Clinical Innovations:** First-time presentation of results of clinical applications of novel therapeutic or diagnostic approaches to heart rhythm disorders.

3. **Late-Breaking Clinical Trials Updates and Registries:** Follow-up analyses from prospective, randomized clinical trials or first-time presentation of high-impact information from multicenter clinical registries or observational studies.

4. **Late-Breaking Science:** Innovative research that includes the latest breakthroughs in basic and/or clinical science that could have a significant impact on clinical practice.

ABSTRACT SUBMISSION AND PREPARATION GUIDELINES

Abstract Title

- An abstract must have a short specific title (containing no abbreviations) that indicates the nature of the investigation.
- Titles should **not** include the authors' names.
- Always use correct title case (e.g., Only the Best of the Best in Medicine Study Electrophysiology).

Abstract Author

The Submitting Author is the Presenting Author. All correspondence for the abstract will be directed to the Submitting Author, their information should be reviewed to ensure that current and correct email address information is listed. This designation should be carefully considered before initiating the abstract submission process. Once the abstract has been submitted, the Submitting /Presenting Author cannot be changed.

- Only one investigator per trial may be considered the Presenting Author.
- The Submitting Author must guarantee that all co-authors are familiar with the data, agree with the stated results, and have agreed to be included as authors.
- If an investigator belongs to multiple submissions, the investigator's name must be identical in each submission. This will ensure consistency and assist in the indexing process for all #HRS2021 electronic and printed materials.
- A completed submission constitutes a commitment by an investigator to present if accepted.

Abstract Text

When entering text, please remember:

- Use generic drug names.
- Do not begin sentences with numerals.
- Standard abbreviations may be used without definition. Non-standard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
- Do not include references, credits, or grant support.

- Do not include the names or personal information of any patient participating in the study or trial.

Please note that because of the text box system, you will not be able to upload your abstract to the Abstract Submission Site; you must either type the text in or cut and paste the text from another document. You will still be able to upload images and create tables the same way as before.

Abstract Data

- Multiple abstracts appearing to be redundant versions of a single study will be rejected.
- Abstracts are not eligible for consideration if published prior to Heart Rhythm 2021. Abstracts may not be presented at Heart Rhythm 2021 if they are substantially similar to material presented at a major international meeting held prior to Heart Rhythm 2021.
- Individuals who have submitted abstracts to other major international meetings and are awaiting notification of acceptance may also submit abstracts to the Heart Rhythm Society for consideration for Heart Rhythm 2021; however, upon acceptance from another organization, it is the responsibility of the author to notify the Heart Rhythm Society office by **Thursday, June 10, 2021, 11:59 p.m. ET** to withdraw the abstract.
- The Heart Rhythm 2021 Program Committee endorses the position of the American Association for the Advancement of Science in requiring assurances of the responsible use of animals in research (AAAS Resolution: Use of Animals in Research, Testing, and Education). All submissions must follow these guidelines.
- Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association (WMA Declaration of Helsinki).
- The Presenting Author must ensure that all co-authors are familiar with the data, agree with the stated results, and have agreed to be included as authors. The Heart Rhythm Society reserves the rights of reproduction, distribution, display and derivatives in both print and digital format. Upon their abstract's acceptance, authors will be asked to read and comply with the Heart Rhythm Society's Release and Authorization for CD-ROMs, Webcasts, and Enduring Products.
- **Industry Abstract Submissions:** In accordance with ACCME Standards of Commercial Support, employees and owners of commercial interests are prohibited from controlling content for CME-certified activities, including poster presentations or oral abstract presentations. All submissions are required to focus on science and research and not products or services. Abstract presentation may not be sales presentations and/or endorsement for products or services.
- SEC Exception: A publicly traded company may determine that it is legally required to disclose certain data or other information from a confidential abstract in advance of the public release date to satisfy requirements of the U.S. Securities and Exchange Commission or a corresponding regulatory body in a country where the company's stock is traded (collectively, "SEC"). This need typically arises when there is a substantial likelihood that the information would be considered by a reasonable investor in the company to significantly alter the total mix of information made available to the investor.
- The abstract is still eligible for inclusion at the Heart Rhythm 2021 meeting provided that the company submits to HRS, in advance of the release, a letter signed by the company's legal counsel that contains the abstract title, indicates the format/nature of the public disclosure, and advises that (a) public disclosure of the information is necessary for the company to comply with applicable securities laws, and (b) the information disclosed is the minimum necessary for such compliance. HRS also requires that the lead author be copied on the request.

Abstract Format

The total number of characters allowed for the submission is 2500. The character count only includes the abstract title, text, tables and/or images. The character count does not include author(s) information and spaces. As you enter text into the abstract title, a counter deducts characters from the total allowable number of characters.

The Abstract Body text is to be provided as follows:

Introduction:
Methods:
Application:
Next Steps/Future:

Table/Graphics:

Characters are also deducted when you create a table or upload a graphic. The number of characters deducted for each table or graphic is 500. Please be sure that any text included in the graphic will be legible at the size you define for the graphic.

Figures:

Figures should be submitted in one of the following file formats: EPS, TIFF, or JPEG. For TIFF or JPEG files, the resolution should be

Line art: 1000 dpi
Photos: 300 dpi
Combination line/half-tones: 500 dpi

Abstract Revisions

- Carefully proofread the abstract content and make any necessary revisions before the submission deadline date.
- To ensure that the abstract receives proper scientific consideration, please make sure that the abstract is submitted to the appropriate category. This determines which team grades the abstract. If you select the appropriate category, you are more likely to be graded by peers with similar interests.
- Resubmission of an abstract that is corrected or changed is not possible after the submission deadline date.

Accepted Submissions

General Information

- Acceptance/Rejection Notification: Disposition announcements will be sent via email on **June 7, 2021** to the investigator submitting the late breaking trial.
- Accepted Late-Breaking Clinical Trials abstracts are embargoed until the time of presentation. This means that the Society will release these abstracts the day of the presentation.
- The Heart Rhythm Society reserves the rights of reproduction, distribution, display and derivatives in both print and digital format. Co-authors reserve all proprietary rights other than copyright, such as patent rights and the right to use all or part of the application in future works of their own.
- Titles and presenters will be listed online in the #HRS2021 Program/Itinerary Planner. A copy of the abstracts will be handed out at the beginning of each Late-Breaking Clinical Trials Session.
- The Late-Breaking Clinical Trial abstracts will be published on the **HeartRhythm** website shortly after #HRS2021 and included in the **HeartRhythm** journal.
- Authors of accepted abstracts are encouraged to submit full articles of their findings to **HeartRhythm** for expedited peer review and potential publication in the journal soon after the presentation. See the **HeartRhythm** author guidelines for information on manuscript preparation and submission.
- Disclosure of Relationships: The presenting author will be required to provide the Heart Rhythm Society with the relationships they need to disclose.

Registration

- The presenter of the trial will be required to register for #HRS2021 and will be charged a reduced registration rate; please visit the Registration & Housing webpage for more information. Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter. Only one author per abstract is considered the presenter. Co-Author(s) listed on the abstract do not receive reduced rates towards registration. For more information, visit the Faculty Resources section of the Heart Rhythm Society's website at www.heartrhythm.com.
- All expenses incurred by the presenter for submission and presentation are the responsibility of the presenter.

Presentation

- The submitting investigator will be asked to reconfirm all co-author information, supply presentation information and inform the Heart Rhythm Society staff of any additional audiovisual needs. PowerPoint presentations have become the standard for #HRS2021 meeting. Additional information will be provided with acceptance information.
- All presenters must display a slide at the beginning of their presentation indicating disclosure information that may be applicable. Detailed information about slides and disclosing relationships will be provided to all presenters.
- All presentations and discussions must be conducted in English.

Questions? If you have any questions about submitting an abstract for presentation at Heart Rhythm, please contact Heart Rhythm staff at abstracts@hrsonline.org